Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
July 14, 2015 08:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 14, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix") today announced the pricing of an underwritten public offering of 2,325,000 shares of its common...
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
July 13, 2015 16:02 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 13, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix") today announced that it intends to offer shares of its common stock in an underwritten public...
Tonix Pharmaceuticals Presents Non-clinical Data on TNX-201 at the 57th Annual Scientific Meeting of the American Headache Society
June 22, 2015 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
- TNX-201 demonstrates significant analgesic effects in animal models of migraine and chronic pain -
- TNX-201 targets the imidazoline-1 receptor and may represent a novel approach to the...
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg
June 17, 2015 07:15 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 17, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix") today reported that the U.S. Food and Drug Administration (FDA) has conditionally accepted the...
Tonix Pharmaceuticals Initiates Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache
June 16, 2015 07:15 ET
|
Tonix Pharmaceuticals Holding Corp.
– Frequent episodic tension-type headache estimated to afflict 75 million Americans –
– Top-line results expected 4Q 2015 –
NEW YORK, June 16, 2015 (GLOBE NEWSWIRE) --...
Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR
June 11, 2015 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
– Results Further Illustrate Efficacy and Tolerability Profile of TNX-102 SL in Fibromyalgia –
– TNX-102 SL Currently Being Evaluated in a Phase 3 Study in Fibromyalgia...
Tonix Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference
May 28, 2015 08:40 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 28, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress...
Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
May 26, 2015 15:45 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix"), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic...
Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry
May 15, 2015 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 15, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix") today presented results from non-clinical studies at the 2015 Annual Meeting of the Society of...
Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
May 13, 2015 06:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 13, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix") announced today that it has begun a Phase 3 clinical study of TNX-102 SL (cyclobenzaprine HCl...